Revision as of 14:01, 29 April 2015 edit Monkbot (talk \| contribs) Bots 3,695,952 edits m →Further reading: Task 7: replace et al. in author/editor parameters with \|display-authors=etal or \|display-editors=etal; ← Previous edit		Revision as of 14:36, 26 June 2015 edit undo Oceanflynn (talk \| contribs) Autopatrolled, Extended confirmed users 56,167 edits No edit summary Next edit →
Line 18: == Therapeutic applications == The drug [[eculizumab]] (trade name '''Soliris''') prevents cleavage of C5 into C5a and C5b.<ref>{{cite journal \| title=Eculizumab\| author=Dubois E, Cohen A\| journal=Br J Clin Pharmacol\| year=2009\| volume=68\| pages=318–319\| pmc=2766470 \|doi=10.1111/j.1365-2125.2009.03491.x \| issue=3 \| pmid=19740388}}</ref> == Complement system pathway ==

Complement component 5: Difference between revisions